» Articles » PMID: 38200158

Advances in the Treatment of Malignant Ascites in China

Overview
Specialties Critical Care
Oncology
Date 2024 Jan 10
PMID 38200158
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Malignant ascites (MA) often occurs in recurrent abdominal malignant tumors, and the large amount of ascites associated with cancerous peritonitis not only leads to severe abdominal distension and breathing difficulties, but also reduces the patient's quality of life and ability to resist diseases, which usually makes it difficult to carry out anti-cancer treatment. The exploration of MA treatment methods is also a key link in MA treatment. This article is going to review the treatment of MA, to provide details for further research on the treatment of MA, and to provide some guidance for the clinical treatment of MA.

Method: This review analyzes various expert papers and summarizes them to obtain the paper.

Result: There are various treatment methods for MA, including systemic therapy and local therapy. Among them, systemic therapy includes diuretic therapy, chemotherapy, immunotherapy, targeted therapy, anti angiogenic therapy, CAR-T, and vaccine. Local therapy includes puncture surgery, peritoneal vein shunt surgery, acellular ascites infusion therapy, radioactive nuclide intraperitoneal injection therapy, tunnel catheter, and intraperitoneal hyperthermia chemotherapy. And traditional Chinese medicine treatment has also played a role in enhancing efficacy and reducing toxicity to a certain extent.

Conclusion: Although there has been significant progress in the treatment of MA, it is still one of the clinical difficulties. Exploring the combination or method of drugs with the best therapeutic effect and the least adverse reactions to control MA is still an urgent problem to be solved.

Citing Articles

Research progress and treatment status of malignant ascites.

He J, Zhang H Front Oncol. 2024; 14:1390426.

PMID: 39737405 PMC: 11682990. DOI: 10.3389/fonc.2024.1390426.


Malignancy of Malignant Ascites: A Comprehensive Review of Interplay between Biochemical Variables, Tumor Microenvironment and Growth Factors.

Jacob R, A S, Abdul Razack N, Prabhuswamimath S Asian Pac J Cancer Prev. 2024; 25(10):3413-3420.

PMID: 39471006 PMC: 11711360. DOI: 10.31557/APJCP.2024.25.10.3413.

References
1.
Ayantunde A, Parsons S . Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007; 18(5):945-9. DOI: 10.1093/annonc/mdl499. View

2.
Saif M, Siddiqui I, Sohail M . Management of ascites due to gastrointestinal malignancy. Ann Saudi Med. 2009; 29(5):369-77. PMC: 3290049. DOI: 10.4103/0256-4947.55167. View

3.
Becker G, Galandi D, Blum H . Malignant ascites: systematic review and guideline for treatment. Eur J Cancer. 2006; 42(5):589-97. DOI: 10.1016/j.ejca.2005.11.018. View

4.
Hisanaga T, Shinjo T, Imai K, Katayama K, Kaneishi K, Honma H . Clinical Guidelines for Management of Gastrointestinal Symptoms in Cancer Patients: The Japanese Society of Palliative Medicine Recommendations. J Palliat Med. 2019; 22(8):986-997. DOI: 10.1089/jpm.2018.0595. View

5.
Nowak M, Klink M . The Role of Tumor-Associated Macrophages in the Progression and Chemoresistance of Ovarian Cancer. Cells. 2020; 9(5). PMC: 7290435. DOI: 10.3390/cells9051299. View